Article Per Year (5 Year)
p-Index From 2021 - 2026
1.704
P-Index
This Author published in this journals
All Journal Folia Medica Indonesiana Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya Buletin Farmatera Biomolecular and Health Science Journal CURRENT INTERNAL MEDICINE RESEARCH AND PRACTICE SURABAYA JOURNAL Indian Journal of Forensic Medicine & Toxicology Vision Science and Eye Health Journal Hang Tuah Medical Journal
Rahmawati, Lita Diah
Bagian Penyakit Dalam Poliklinik Reumatologi FK Universitas Airlangga - RSUD Dr.Soetomo
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health Other

Published : 12 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 12 Documents
Search

 1   2 
Efficacy of Ozoralizumab vs. Golimumab for Rheumatoid Arthritis: A Systematic Review Fithriyah, Nathania Elma; Rahmadhani, Khafiyah Hikmah; Susanti, Luthfiana Rofhani; Mustika, Arifa; Lita Diah Rahmawati; Wungu, Citrawati Dyah Kencono
Current Internal Medicine Research and Practice Surabaya Journal Vol. 6 No. 2 (2025): CURRENT INTERNAL MEDICINE RESEARCH AND PRACTICE SURABAYA JOURNAL
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/cimrj.v6i2.66406

Abstract

Introduction: Rheumatoid arthritis, a systemic autoimmune disease, affects 13% of the world population. As a well-established therapy, golimumab provides a key benchmark for assessing novel biological treatments. In contrast, ozoralizumab represents an innovative therapeutic approach. This study aimed to comprehensively elucidate the efficacy of golimumab and ozoralizumab in reducing rheumatoid arthritis disease activity. Methods: Literature searches were conducted throughout PubMed, Cochrane, and Web of Science using Boolean operators, covering available records from database inception until October 2024. The literature search was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The included studies were randomized controlled trials (RCT) evaluating the efficacy of ozoralizumab or golimumab for rheumatoid arthritis. Five studies from 2015 to 2022 were obtained and assessed using the Cochrane Risk of Bias 2 (ROB2) tool. Results: The five studies consisted of two ozoralizumab trials and three golimumab trials conducted in Japan and the United States, involving 2,305 participants. All included studies exhibited a low risk of bias based on assessments undertaken using the ROB2 tool. The differences in Disease Activity Score-28 (DAS28) remission rates between ozoralizumab and placebo were 42.6% in one study and 6.3% in the other, whereas golimumab mainly showed smaller differences versus placebo across three studies (4.6%, 5.9%, and 10.4%). Conclusion: This study demonstrates DAS28 remission in rheumatoid arthritis patients receiving either ozoralizumab or golimumab therapy. Nonetheless, further direct statistical studies are essential to determine which therapy is superior and under what circumstances it should be administered.   Highlights: 1. This study provides robust evidence that establishes ozoralizumab as a novel tumor necrosis factor-alpha (TNF-α) inhibitor for rheumatoid arthritis. 2. According to the findings, ozoralizumab may be a clinician's choice due to its comparable efficacy and potential advantages over golimumab.
Psoriatic arthritis and Hashimoto's thyroiditis in a patient presenting with major depression and subclinical hyperthyroidism: A case report Rahmawati, Lita Diah; Mahdi, Bagus Aulia
Qanun Medika - Jurnal Kedokteran FK UMSurabaya Vol 8 No 01 (2024): Qanun Medika Vol 08 No 01 January 2024
Publisher : Universitas Muhammadiyah Surabaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30651/jqm.v8i01.17778

Abstract

Psoriatic arthritis (PsA) is a chronic, deforming arthritis associated with psoriatic skin lesions. Numerous patients with PsA carry other co-existing chronic diseases, adding to their overall disease burden and affecting the patient’s quality of life. Depression is a common illness known to coexist in about 20% of patients with PsA. Long-term inflammation conditions can make patients more depressed and make the treatment more difficult. Cushing Syndrome (CS) is a complication of long-term treatment due to the exposure of glucocorticoids given to turn the hypothyroid condition into hyperthyroid because hypercortisolism in humans lowers TSH secretion and TSH pulse amplitude. When PsA combines with depression and CS, it will create complex conditions and treatments. The complexity is all about how we control the disease activity of PsA and the vicious circle of an inflammatory process that is difficult to control. Conventional treatment will fail, and targeted therapy with monoclonal antibodies such as anti-IL-17 Secukinumab, is needed. Secukinumab as an anti-IL-17 will block the inflammation pathway from interleukin-17, decrease the inflammation process, and improve the symptoms of PsA. We report a patient with psoriatic arthritis and Hashimoto's thyroiditis (HT) with a major depressive episode with CS and subclinical hyperthyroidism successfully treated with Secukinumab.
Co-Authors Arifa Mustika Aryati Aryati Asri Insanur Rahma Devi Sarah Intan Permatasari Elfrida Ratnawati Familia, Adidia Carina Fithriyah, Nathania Elma Hersih Srinowati Ilham Wildan Ahmad Mahdi, Bagus Aulia Nasution, Huwainan Nisa Rahmadhani, Khafiyah Hikmah SUKACITA TEHUPURING Susanti, Luthfiana Rofhani Wardhana, Teddy Heri Wungu, Citrawati Dyah Kencono Wungu, Citrawati Dyah Kencono Yudha, Cahaya Prasta Yulia Nadar Indrasari Zuhria, Ismi